Nektar Therapeutics(GB:0UNL)
$37.66-0.14 (-0.37%)
GB:0UNL
Nektar Therapeutics hedge funds
$37.66
At close:-0.14 (-0.37%)
Nektar Therapeutics (0UNL) Hedge Fund Trading Activity
0 Followers
Trend: ▲ Hedge Funds Increased Holdings by 443.6K Shares Last Quarter
Hedge Fund Holdings in 0UNL
Based on the 13F filings of 489 Hedge Funds tracked by TipRanks, as submitted to the SEC.
Hedge Fund Confidence Signal
Hedge Fund Activity
Activity
Star Ranking
 Theofanis Kolokotrones | PRIMECAP Management Co | Reduced | -3.08% | $11,844,742 | <0.01% | ||
| Travis Knapp Anderson | Gilder Gagnon Howe & Co LLC. | Reduced | -7.35% | $8,807,008 | 0.09% | ||
| Michael Rockefeller | Woodline Partners LP | Reduced | -55.38% | $4,397,120 | 0.02% | ||
| Andrew J.M. Spokes | Farallon Capital Management, L.L.C. | Sold Out | -100.00% | $33,443,480 | 0.00% |
FAQ
Which hedge funds hold Nektar Therapeutics?
The hedge funds that hold the most shares in Nektar Therapeutics are Theofanis Kolokotrones, Travis Knapp Anderson and Michael Rockefeller.
Are hedge funds buying or selling GB:0UNL?
In the last quarter hedge funds have Increased their holdings in Nektar Therapeutics by 443.6K shares.
Where can I see a list of the best rated hedge funds?
You can see a list of the best hedge funds here.
Who is the best-performing hedge fund manager?
The top-rated hedge fund managers can be seen here: Top Hedge Fund Managers
Does Warren Buffet hold shares in Nektar Therapeutics stock?
Warren Buffet currently does not own shares in Nektar Therapeutics.
What is a 13F filing, and how does it help investors?
A 13F form, also known as a "Report of Investment Manager," is a quarterly report that investment advisors registered with the Securities and Exchange Commission (SEC) must file if they manage at least $100 million in assets. The 13F form lists all of the publicly traded securities that the investment advisor owns as of the end of the reporting period. To read more about the 13F, click here
